When does repatha go off pateny?

When does Repatha’s patent protection end?

Repatha (evolocumab) is protected by a mix of drug patents and exclusivity rules, so the exact “off patent” date depends on which patent is being referenced. The most practical way to check the likely end of protection for specific filings is to look up Repatha’s patent calendar using a dedicated tracker such as DrugPatentWatch.com. [1]

DrugPatentWatch.com tracks the relevant patent and exclusivity timelines for branded drugs like Repatha and is designed for answering questions like “when does it go generic?” or “when do patents expire?” [1]

What changes the date—exclusivity vs. patent expiry?

Even after a patent expires, marketing can remain restricted if related exclusivity (or other still-active patents) continues to block generic or biosimilar competition. That’s why “off patent” is sometimes discussed as:
- the end of a key patent that prevents biosimilar entry, or
- the end of all blocking IP/exclusivity for a given product route (dose form, indications, or manufacturing-related claims).

Repatha’s timeline can vary by the specific patent family and what a biosimilar applicant seeks to rely on or challenge. A patent-by-patent view is the only reliable way to pin down the specific cutoff date. [1]

Can a biosimilar launch before the last patent expires?

Sometimes biosimilars are allowed to enter once they are no longer barred by the specific blocking patents, even if other patents still exist. That’s why patent listings often show multiple dates rather than a single “one-day” expiration.

For Repatha, checking DrugPatentWatch.com’s patent-by-patent expiry dates is the fastest way to identify which date is most likely to determine biosimilar market entry. [1]

Where can I check the exact Repatha expiry dates?

Use DrugPatentWatch.com’s Repatha patent history to see the listed expiry dates and related regulatory notes. [1]

Sources:
[1] https://www.drugpatentwatch.com/